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Abstract
Aims—We have previously shown that the (±)-[13C]-pantoprazole breath test is a promising 
noninvasive probe of CYP2C19 activity. As part of that trial, plasma, breath test indices and 
CYP2C19 (*2, *3 and *17) genotype were collected. Here, we examined whether [13C]-
pantoprazole exhibits enantioselective pharmacokinetics and whether this enantioselectivity is 
correlated with indices of breath test.
Methods—Plasma (−)- and (+)-[13C]-pantoprazole that were measured using a chiral HPLC 
were compared between CYP2C19 genotypes and correlated with breath test indices.
Results—The AUC(0-∞) of (+)-[13C]-pantoprazole in PM (*2/*2, n=4) was 10.1- and 5.6- fold 
higher that EM (*1/*1or *17, n=10) and IM (*1/*2or *3, n=10) of CYP2C19 respectively 
(p<0.001). The AUC(0-∞) of (−)-[13C]-pantoprazole only significantly differed between PMs and 
EMs (1.98-fold; p=0.05). The AUC(0-∞) ratio of (+)-/(−)-[13C]-pantoprazole was 3.45, 0.77 and 
0.67 in PM, IM and EM genotypes respectively. Breath test index, Delta Over Baseline (DOBmax) 
show significant correlation with AUC(0-∞) of (+)-[13C]-pantoprazole (Pearson’s r = 0.62; 
p<0.001).
Conclusions—[13C]-pantoprazole exhibits enantioselective elimination. (+)-[13C]-pantoprazole 
is more dependent on CYP2C19 metabolic status and may serve as a more attractive probe of 
CYP2C19 activity than (−)-[13C]-pantoprazole or the racemic mixture.
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Introduction
The human cytochrome P450 (CYP) CYP2C19 metabolizes several clinically important 
drugs, including those with a narrow therapeutic range.1–3 This enzyme is also critical in the 
metabolic activation of some prodrugs such as clopidogrel,4 cyclophosphamide,5,6 and 
thalidomide7 to pharmacologically active metabolites. The activity of this enzyme varies 
widely among individuals, leading to substantial differences in the clearance or metabolic 
activation of its substrates among patients. This variability is mainly controlled by 
functionally relevant genetic variations in the CYP2C19 gene coding for the enzyme.1–3 In 
addition, nongenetic factors that include exposure to drugs that directly inhibit the CYP2C19 
enzyme or enhance its expression contribute to this variability. Clinical studies suggest that 
differences in CYP2C19 metabolic status have important clinical implications in terms of 
efficacy or adverse effects for a number of drugs that include proton pump inhibitors,8 
clopidogrel,9,10, voriconazole,11 diazepam,1,12, cyclophosphamide,6 thalidomide,7 and 
citalopram.13 It follows that knowledge of CYP2C19 metabolic status is important to 
optimize therapy and avoid adverse effects of drugs metabolized by this enzyme.
Recently, we and others have tested and demonstrated that stable isotope labeled racemic 
(±)-[13C]-pantoprazole breath test is a promising tool to assess CYP2C19 metabolic 
status.14–16 This test has a number of practical advantages (captures genetic and nongenetic 
causes of CYP2C19 activity, noninvasiveness, easy and rapid to perform) and has the 
potential to offer greater clinical utility than existing approaches (e.g. genetic tests). Studies 
have shown that the pharmacokinetics of stable isotope unlabelled pantoprazole is 
enantioselective and that the (+)-enantiomer is more dependent on CYP2C19 activity than 
the (−)-enantiomer of pantoprazole.17 Whether the metabolism and pharmacokinetics of the 
stable isotope racemic [13C]-labeled pantoprazole exhibits enantioselectivity similar to that 
of [13C]-unlabeled pantoprazole has not been determined.
In this study, we have performed additional studies to test the hypothesis that [13C]-labeled 
pantoprazole is metabolized the same as the [13C]-unlabeled pantoprazole such that its 
pharmacokinetics is stereoselective. If so, the metabolism of the (+)-[13C]-enantiomer, 
which is more exclusively catalyzed by CYP2C19 than the (−)-[13C]-enantiomer or racemic 
mixture may be a better candidate for further development as a CYP2C19 phenotyping tool. 
The secondary purpose of the study is to relate the pharmacokinetics of each enantiomer 
with breath test indices.
Methods
In a previous study, we investigated the utility of racemic [13C]-pantoprazole breath test as a 
marker of CYP2C19 activity.14 As part of that clinical trial, plasma for pharmacokinetic 
studies as well as breath test indices and CYP2C19 (*2, *3 and *17) were collected. The 
present report focuses on determination of enantioselective pharmacokinetics of [13C]-
pantoprazole in the plasma samples collected from the completed trial. The trial which was 
detailed in our previous publication14 is briefly described below.
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Study Subjects
A total of 25 healthy male (10) and female (15) volunteers, of Asian origin (18–49 years old, 
with body weight of at least 110 pounds and body mass index ≤30) and pre-genotyped for 
CYP2C19*2, *3, and *17 alleles were studied at the outpatient clinic of the Indiana 
University School of the Medicine Indiana Clinical Research Center (ICRC). This study was 
approved by the Institutional Review Board of the Indiana University. Investigative Device 
Exemption application G070004 to conduct the study was also approved by the Food and 
Drug Administration. This trial was registered at http://www.ClinicalTrials.gov (identifier: 
NCT00668902). All study subjects provided written informed consent before participation. 
Details of the inclusion criteria of the participants were published previously.14
Study Design
This was an open-label, single-dose clinical trial. Eligible subjects were administered a 
single 100mg oral dose of (±)-[13C]-pantoprazole sodium-sesquihydrate (4-O-[methyl-13C]-
pantoprazole, 99%; CLM-7831-SP; lot#. PR-17177; Cambridge Isotope Laboratories, Inc., 
Andover, MA) with 2.1 g sodium bicarbonate. Breath samples were collected at baseline 
and at 2.5, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, and 120 min post dosing. Venous blood 
samples (10 ml) were collected at baseline and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, and 
12 h after [13C]-pantoprazole administration. Plasma was separated by centrifugation and 
stored frozen at −80°C until use.
CYP2C19 Genotyping
Extraction of genomic DNA and genotyping for CYP2C19*2, *3 and *17 were reported 
previously.14 In brief, genomic DNA was extracted from human whole blood with the 
QIAGEN DNA MiniKit (QIAGEN, Valencia, CA) and genotyping for CYP2C19*2 
(rs4244285), CYP2C19*3 (rs4986893), and CYP2C19*17 (rs12248560) by TaqMan Assay-
Reagents Allelic Discrimination Kits (Applied Biosystems, Foster City, CA) according to 
the supplier's instructions.
Quantitation of 13CO2
The concentrations of 13CO2 and 12CO2 in exhaled breath samples were determined using 
the UBiT-IR300 IR spectrometry (Meretek Diagnostics, Rockville, MD) equipped with 
interference filters that are wavelength-selective for the absorbance of 13CO2 and 12CO2. 
Enrichment of 13CO2 in expired air was calculated at each sampling point. The delta over 
baseline (DOB) in the 13CO2/12CO2 ratio after [13C]-pantoprazole relative to predose 
(baseline) 13CO2/12CO2 ratio was calculated as described elsewhere by our group.14
Measurement of [13C]-Pantoprazole
Plasma concentrations of [13C]-pantoprazole enantiomers were measured using a previously 
described method, with slight modification.14 Plasma samples were extracted with 6 ml of 
ethyl acetate, after the addition of 20 μl of internal standard (50 μg/ml phenacetin) and 250 
μl of 2% ammonium hydroxide. The samples were then vortexed and spun and the resultant 
supernatant was transferred to a new tube to be evaporated. The dried residue was 
reconstituted with 100 μl of acetonitrile and 50 μl were injected onto the HPLC. Separation 
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was performed using a Chiralcel OJ-RH column (4.6mmx150mm) (Chiral Technologies Inc. 
West Chester, PA) and a mobile phase consisting of 75% 50mM sodium perchlorate and 
25% acetonitrile (flow rate, 0.5 ml/min). Analytes were detected by UV at 290nm. (Figure 
1)
Quantification of [13C]-pantoprazole was performed using a standard curve generated in 
blank plasma. The limit of quantification of the assay was 0.025 μg/ml. The inter-day and 
intra-day coefficient of variation (% CV) of the assay was less than 20%.
Analysis of Breath Test Indices and Pharmacokinetics
Breath test indices and pharmacokinetic parameters were determined by fitting the DOB 
data or plasma concentration data to a standard noncompartmental analysis using WinNonlin 
professional software (version 5.01; Pharsight, Mountain View, CA) as described before.14
Statistical Analysis
Continuous variables were summarized by groups using descriptive statistics. Differences in 
pharmacokinetic parameters and breath test indices among different genotypes of CYP2C19 
were analyzed by the ANOVA test with Dunnett's multiple comparison post test assuming 
the patients were sampled from a Gaussian population. Pearson's correlation analysis was 
performed to determine relationships between breath indices and pharmacokinetic 
parameters. All statistical tests were conducted using PASW Statistics 17.0 (SPSS Software 
Inc., Chicago, IL). A p-value of p < 0.05 was considered statistically significant.
Results
In this study, 24 subjects had both pharmacokinetic and breath test indices and were 
included for analysis. The genotype predicted CYP2C19 phenotypes were: 4 PM (*2/*2), 10 
IM (*1/*2, n=9; and *1/*3, n=1) and 10 EM (*1/*1, n=9; and *1/*17, n=1). One poor 
metabolizer (PM) of CYP2C19 subject that was included in the previous publication14 was 
excluded because of unavailability of plasma samples. The demographic characteristics 
among the different genotypes were provided previously.14
The plasma concentration time profile of [13C]-pantoprazole enantiomers in the three groups 
of genotypes is shown in Figure 2. The corresponding pharmacokinetic parameters are listed 
in Table 1. Statistically significant differences in the elimination half-life (p<0.001), 
AUC(0-∞) (<0.05) and weight adjusted oral clearance (<0.05) of (−)-[13C]-pantoprazole 
were observed among the 3 genotypes [PM (n=4), IM (n=10), EM (n=10)]. Post-hoc 
analysis showed that PMs had a significantly longer half-life, higher AUC(0-∞) and lower 
oral clearance than EM subjects; no difference was observed between IMs versus PMs or 
IMs versus EMs except for the elimination half-life (Table 1), but these did not reach 
statistical significance. A more pronounced effect of CYP2C19 genotypes was observed on 
the elimination parameters of (+)-[13C]-pantoprazole (Table 1). The elimination half-life, 
AUC(0-∞), and weight adjusted oral clearance of (+)-[13C]-pantoprazole were markedly and 
significantly different among the three genotype groups (p<0.001; ANOVA). Post-hoc 
analysis revealed that PM subjects had significantly higher AUC (p < 0.001), longer half-life 
(p < 0.001) and lower oral clearance (p < 0.01) compared to EM of CYP2C19; higher AUC 
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(p < 0.001) and longer half-life (p < 0.001) were also observed in PM compared to IM, but 
the oral clearance was not statistically significant between these groups (Table 1).
The impact of genotype on ratios of (+)−/(−)-[13C]-pantoprazole concentrations is shown 
(Figure 3). The stereoselectivity is much more pronounced in the PM group than EM and IM 
groups. Accordingly, the AUC ratios of (+)−/(−)-[13C]-pantoprazole (with 95% CI) were 
3.49 (2.26,4.72), 0.77 (0.72,0.84) and 0.62 (0.52,0.73) in PM, IM and EM respectively; 
similarly the ratios of the elimination half-lives were 2.99 (1.89,4.09), 0.78 (0.62,0.94) and 
0.75 (0.54,0.97) respectively. No stereoselectivity was observed with regard to Vd/F. (+)-
[13C]-pantoprazole was more dependent on CYP2C19 function than that of (−)-[13C]-
pantoprazole was. Thus, the impact of PM on (+)-[13C]-pantoprazole elimination was much 
greater than IM and EMs compared to the (−)-[13C]-pantoprazole counterpart. As a result, 
there is a strong gene-dose effect in (+)-[13C]-pantoprazole more so than with (−)-[13C]-
pantoprazole.
The results of the (±)-[13C]-pantoprazole breath test reported previously14 were recalculated 
and summarized in Table 2. As with the PK parameters, the breath test indices were 
significantly affected by CYP2C19 genotypes (Table 2). Correlation analyses between 
pharmacokinetic parameters and breath test indices are listed in Table 3. Breath test indices 
show no or marginal correlation with (−)-[13C]-pantoprazole elimination parameters, while 
statistically significant correlations were observed with the elimination of (+)-[13C]-
pantoprazole enantiomer, again pointing towards a much bigger role of CYP2C19 in (+)-
[13C]-pantoprazole elimination and breath test indices. For example, DOBmax and 
AUC(0-120) were more significantly correlated with AUC(0-∞) of (+)-[13C]-pantoprazole 
(Pearson correlations: −0.46 & −0.68) than they were with (−)-[13C]-pantoprazole (Pearson 
correlations: −0.40 & −0.35 for DOBmax and AUC(0-120), respectively) (Tables 3 & Figure 
4).
Discussion
In the present study, we have demonstrated that (±)-[13C]-pantoprazole showed 
stereoselective metabolism, the (+)-[13C]-pantoprazole is preferentially catalyzed by 
CYP2C19 and that breath test indices correlate best with the elimination of (+)-[13C]-
pantoprazole more than that of (−)-[13C]-pantoprazole. These results demonstrate that stable 
isotope labeled and unlabeled pantoprazole are metabolized by the same mechanism. 
Incorporation of the [13C]-label at the O-methyl site of pantoprazole does not alter patterns 
of stereoselective metabolism of pantoprazole. The results further suggest that (+)-[13C]-
pantoprazole breath test may be a better selective probe of CYP2C19 activity than the 
racemic mixture.
That CYP2C19 is the major clearance mechanism (up to 80% of the administered dose) for 
pantoprazole and other proton pump inhibitors has been well established.18–20 Pantoprazole 
is O-demethylated primarily by CYP2C19 to 4-hydroxypantoprazole and a methyl 
group.18,20 The hydroxylated metabolite formed undergoes rapid sulfation, while the methyl 
group passes through the carbon pool before it eventually traverses to the lung and is 
exhaled.14,18 A minor pathway of pantoprazole involves CYP3A-mediated sulfoxidation to 
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pantoprazole sulfone. In a previous report14 we have shown that the (±)-[13C]-pantoprazole 
breath test indices and pharmacokinetics were significantly associated with CYP2C19 
genotypes, suggesting a major role of CYP2C19 in the metabolism of (±)-[13C]-
pantoprazole and isotope unlabeled pantoprazole. Since pantoprazole is a chiral molecule 
and its pharmacokinetics show enantioselectivity,21 we tested in this study whether (±)-
[13C]-pantoprazole metabolism is also enantioselective. Our data show that, indeed, the 
metabolism of (±)-[13C]-pantoprazole is enantioselective and that this is mainly dependent 
on CYP2C19 activity. These data and our previous report suggest that incorporation of the 
[13C]-label at the O-methyl site of pantoprazole alters neither the metabolic patterns of 
racemic (±)-[13C]-pantoprazole nor its stereoselective elimination.
The pattern of stereoselectivity of the [13C]-labeled pharmacokinetic data from the present 
study are broadly consistent with those previously reported for the isotope unlabeled 
pantoprazole by Tanaka et al.21 Specifically, the elimination of (+)-[13C]-pantoprazole was 
more dependent on CYP2C19 activity in both studies compared to that of (−)-[13C]-
pantoprazole. These data concur with the fact that (+)-[13C]-pantoprazole is predominantly 
catalyzed by CYP2C19-mediated O-demethylation in both studies, while CYP3A-mediated 
sulfoxidation contributes significantly to the metabolism of (−)-[13C]-pantoprazole.18,19 
Consistent with the major role of CYP2C19 in (+)-[13C]-pantoprazole elimination compared 
to that of (−)-[13C]-pantoprazole, better correlation of (±)-[13C]-pantoprazole breath test 
indices were observed with the elimination of (+)-[13C]-pantoprazole than with that of (−)-
[13C]-pantoprazole when all data were considered or PMs were excluded. It is also 
interesting to note that both the elimination parameters of (+)-[13C]-pantoprazole and breath 
test indices are more significantly associated with CYP2C19 genetic variation compared to 
those of (−)-[13C]-pantoprazole. Despite this, it is interesting to note that the correlations of 
breath test indices with the exposure of the (+)-enantiomer (Pearson r= −0.46 and −0.68) are 
not perfect. Clearly, our data show that the breath test is generated from both enantiomers 
when (±)-[13C]-pantoprazole is administered. In addition, the [13C] may be distributed with 
time in to the carbon pool of the body and contributing to the relatively lower correlation. It 
is also possible that sequential metabolism via the sulfone metabolite (O-demethylation) also 
contribute to this. Nevertheless, these data suggest that (+)-[13C]-pantoprazole is the main 
source of 13CO2 exhaled in the lung. Therefore, O-demethylation is the primary clearance 
mechanism of (+)-[13C]-pantoprazole, whereas other pathways such as CYP3A-mediated 
sulfoxidation appear to significantly contribute to the metabolism of (−)-[13C]-pantoprazole.
Some of the pharmacokinetic parameters derived from this study [shorter tmax, higher Cmax 
and higher AUC(0-∞)] were different from the study by Tanaka et al.17 However, it is 
difficult to directly compare our values with those of Tanaka et al. First, the doses used were 
different (100 mg in this study versus 40 mg in the other study). Second, the formulations 
used were different (solution in this study versus enteric coated tablet in the Tanaka study). 
The tmax values in this study (0.5 hr) was consistently lower than in the other study, which 
agrees well with the difference in formulations and thus rate of absorption. Third, IM and 
EM were analyzed as EM in the Tanaka study [19] while in our case IM and EM of 
CYP2C19 were analyzed separately. Additional factors that may contribute to this 
discrepancy may include the way the phenotypic groups were classified (genotype-predicted 
phenotype in our study and S-mephenytoin probe activity in the other study.21)
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Concluding Remarks
In summary, we have shown that the metabolism of isotope [13C]-stable labeled 
pantoprazole and unlabeled pantoprazole is similar qualitatively and quantitatively, 
providing a rationale for using the O-demethylation of [13C]-labeled pantoprazole as a 
noninvasive novel biomarker of CYP2C19 activity. Previously, we have performed a 
feasibility study showing that (±)-[13C]-pantoprazole breath test is a reliable marker of 
CYP2C19 activity in healthy volunteers. While this test completely discriminated PM from 
EM and IM of CYP2C19, there was a significant overlap between EM and IM of CYP2C19, 
which could be due to differences in the quantitative contribution of CYP2C19 and 
pathways towards the different enantiomers. The data from the present study indicate that 
(+)-[13C]-pantoprazole is more exclusively metabolized by CYP2C19 than (−)-[13C]-
pantoprazole. Studies are ongoing to test whether (+)-[13C]-pantoprazole breath test is 
superior to (±)-[13C]-pantoprazole breath test to probe CYP2C19 activity.
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Figure 1. 
Representative chromatogram of an EM, showing the separation of both the (−)-[13C]-
pantoprazole and the (+)-[13C]-pantoprazole enantiomers.
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Figure 2. 
Mean (±S.D.) of the plasma concentration versus time curves of (−)-[13C]-pantoprazole (A) 
and (+)-[13C]-pantoprazole (B) after administration of a single 100mg oral dose of (±)-
[13C]-pantoprazole sodium-sesquihydrate to healthy volunteers with PM (n=4), IM (n=10) 
and EM (n=10) genotypes of CYP2C19.
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Figure 3. 
Mean (±S.D.) ratios of plasma concentrations of (+)-[13C]-pantoprazole/(−)-[13C]-
pantoprazole versus time after administration of a single 100mg oral dose of (±)-[13C]-
pantoprazole sodium-sesquihydrate to healthy volunteers with PM (n=4), IM (n=10) and EM 
(n=10) genotypes of CYP2C19.
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Figure 4. 
Correlations of Maximal Delta Over Baseline (DOBmax) with AUC(0-∞) of (−)-[13C]-
pantoprazole (A) and of (+)-[13C]-pantoprazole (B) after administration of a single 100mg 
oral dose of (±)-[13C]-pantoprazole sodium-sesquihydrate to healthy volunteers with PM 
(n=4), IM (n=10) and EM (n=10) genotypes of CYP2C19.
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Table 2
Mean (±95% C.I.) breath test parameters after a single 100mg oral dose of (±)-[13C]-pantoprazole in PM, IM 
and EM genotypes.
PM (n=4) IM (n=10) EM (n=10) p Valuea
tmax (minutes)§ 27.5 (10,50) 30.0 (25,60) 30.0 (20,50) 0.50
Maximum Delta Over Baseline (DOBmax) 0.88** (0.60,1.15) 3.49 (2.64,4.34) 4.44### (3.16,5.72) < 0.01
AUC(0-120) (minutes* DOB) 56.07** (19.85,92.29) 315.40 (242.7,388.1) 378.22### (282.7,473.8) < 0.001
DOBmax/Kg 0.0143 (0.01,0.02) 0.0555 (0.03,0.08) 0.0695# (0.04,0.10) < 0.05
PM vs IM :
*
= p<0.05,
**
= p<0.01,
***
= p<0.001
IM vs EM :
@
= p<0.05,
@@
= p<0.01,
@@@
= p<0.001
PM vs EM :
#
= p<0.05,
##
= p<0.01,
###
= p<0.001
a
= One-Way ANOVA with Dunnett 2-Sided
§
tmax [Median (min,max)]
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